Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
**[68Ga]Ga-NOTA-RT4** is an investigational gallium-68 radiolabeled, NOTA-chelated Trop2-targeting single-domain antibody PET tracer. RT4 is a recombinant His-tag-free single-domain antibody that binds trophoblast cell surface antigen 2, enabling noninvasive PET/CT visualization of Trop2 expression in tumors. The agent is intended as a diagnostic immunoPET radiopharmaceutical and potential companion-imaging tool for selecting or monitoring patients receiving Trop2-targeted cancer therapies, rather than as a therapeutic radioligand. It is being evaluated by Renji Hospital in clinical imaging studies of solid tumors and non-small cell lung cancer.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on [68Ga]Ga-NOTA-RT4.